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ABSTRACT 
 Infection by any of the four dengue virus (DENV) serotypes produces a wide 
spectrum of clinical illness in humans. Differences in clinical manifestation and severity have 
been associated with secondary heterologous infection, patient age and virus serotype. In 
this context, this retrospective study sought to analyze the presentation of dengue in patients 
during the 2014 DENV-4 outbreak affecting the City of Orán, Salta Province, Argentina. 
Demographic data, clinical manifestations and laboratory abnormalities of laboratory-
confirmed dengue patients were compared between age groups and between patients with 
and without warning signs. Of 301 patients with laboratory-confirmed dengue, 37.9% 
presented dengue with warning signs. Although nearly half of all patients had secondary 
DENV infections, no severe dengue cases or deaths were reported. Furthermore, no 
association was found between incidence of warning signs and pre-existing immunity to 
DENV. Pediatric patients were least likely to present warning signs and showed significantly 
decreased risk of fever, retro-orbital pain, arthalgia, diarrhea and thrombocytopenia and 
higher risk of rash compared to older patients. Female patients of all ages were also at 
higher risk of developing several symptoms. The characterization of DENV-4 infection in 
humans, a DENV serotype recently reported in Argentina, revealed differences in clinical 
manifestations, laboratory parameters and the presence/absence of warning signs based on 
age group. Further investigation of these age-related differences should contribute to better 
assessment of dengue disease in at risk populations. This article is protected by copyright. All 
rights reserved 
 
Keywords: dengue virus, epidemiology, pediatric population, disease outcomes, age-related 
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INTRODUCTION 
 
 Dengue virus (DENV) is a flavivirus that produces the most prevalent arthropod-borne 
viral disease in humans. After a lapse in the region-wide vector eradication put in place 
during the mid 20th century, DENV serotypes 1-4 have re-emerged in the Americas, making 
dengue a public health priority 1,2. DENV infection produces a wide range of clinical 
manifestations including both asymptomatic and clinical infection 3. The latter are grouped by 
the World Health Organization (WHO) into three levels of disease severity: dengue without 
warning signs (DWoWS), a febrile illness frequently associated with rash and joint pain; 
dengue with warning signs (DWWS), in which the patient may also experience hemorrhage, 
swelling, hepatomegaly and/or an increase in hematocrit and thrombocytopenia; and the 
potentially fatal severe dengue (SD), which may include severe bleeding, shock, organ 
failure and respiratory distress 4. Differences in clinical manifestations and severity have 
been associated with secondary heterologous DENV infection 5, patient age 6-8 and virus 
serotype 9,10, though the underlying mechanisms of disease enhancement are still not fully 
characterized.  
 Since the re-emergence of DENV in Argentina in 1998, important outbreaks have 
occurred in 3-5 year cycles. The majority of cases occur in Northern provinces, where the 
sub-tropical climate and occasional winter frosts allow for seasonal proliferation of the most 
common DENV vector, Aedes aegypti. Though A. aegypti flight range is extremely limited 11, 
frequent domestic and commercial contact with bordering countries in which DENV is 
endemic can lead to DENV importation and the autochthonous spread of the virus. The city 
San Ramón de la Nueva Orán (also referred to as Orán) is the head of the homonymous 
department; it has a population of approximately 140,000 inhabitants and it is located in the 
province of Salta on the Northwestern border of Argentina, 270 km Northeast of the province 
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capital Salta and 30 km South of Bolivia (Figure 1). Since 1998, the province of Salta has 
experienced outbreaks of all four DENV serotypes; DENV-2 in 1998 12, DENV-1 in 2002, 
DENV-3 in 2003 (specifically in Orán), both DENV-1 and DENV-2 between 2008-2014 13,14, 
and DENV-4 in 2013 and 2014, the latter mainly affected the Northern departments, 
including the Department of Orán 13,15. DENV-4 has been endemic in Central America since 
its introduction to the eastern Caribbean islands in 1981 2. In recent years, DENV-4 has been 
reported in increasingly southern latitudes in South America, and was reported for the first 
time in Argentina in 2010 in a single infection in the province of Santa Fe 16,17.  
 Dengue is considered a pediatric disease in endemic settings 18, where many adults 
have acquired immunity to multiple serotypes through repeated heterotypic infection. 
Because epidemiological studies are primarily conducted in endemic regions 19, studying 
dengue outbreaks in re-emergent, epidemic settings offers an interesting opportunity to 
evaluate clinical manifestations in adults and children who have had similar lifetime exposure 
to DENV. Furthermore, each DENV serotype represents a population of viral genotypes 
whose evolution may influence disease manifestation and patient prognosis. The current 
study describes the clinical manifestations and laboratory abnormalities of children and 
adults in the first autochthonous DENV-4 outbreak in Argentina. 
 
MATERIALS AND METHODS 
 
Study Population 
 This retrospective study was conducted at the regional public San Vicente de Paul 
Hospital between February and June 2014. San Vicente de Paul Hospital is the only high-
complexity hospital in the Department of Orán, which provides medical assistance to the City 
of Orán and surrounding areas, with a catchment population of 170,000 persons. Four 
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private clinics also offer medical care in the municipality. During DENV outbreaks, an 
outpatient care center is created at San Vicente de Paul Hospital to address the unique 
needs of patients with probable dengue infections. The study´s inclusion criteria were: (1) 
presentation for treatment at San Vicente de Paul Hospital´s care center with symptoms 
suggestive of DENV infection; (2) laboratory confirmation of DENV infection by ELISA for IgM 
and NS1; and (3) residence in the municipality of Orán. All of the patients included in the 
study were treated as outpatients. Dengue cases were defined by both the presence of IgM 
(PanBio Dengue IgM Capture ELISA, Australia) and NS1 antigen (Platelia Dengue NS1 Ag, 
Bio-Rad, France) determined by ELISA in acute serum samples. Serotyping was performed 
at the provincial reference laboratory. 
 
Data collection and study variables 
 Data were collected through epidemiological and clinical records and laboratory 
analysis performed during treatment at San Vicente de Paul Hospital´s care center.  
 Illness was defined as DWoWS when patients had laboratory-confirmed DENV 
infection and symptoms that did not fulfill the WHO definition of DWWS or SD. DWWS and 
SD were defined using the WHO guidelines for diagnosis. Demographic variables included 
sex and age: study participants aged 2-14 years were defined as children while patients 15 
years and older were considered adults. 
 The clinical symptoms recorded were: fever, defined as an axial temperature greater 
than or equal to 38◦C; headache; retro-orbital pain: localized pain behind the eye; bipalpebral 
edema: abnormal fluid accumulation in the internal tissue of the eyelid; conjunctival injection: 
congestion and dilation of blood vessels in the sclera causing ocular redness; myalgia: pain 
in response to gentle pressure during physical examination; arthralgia: localized joint pain; 
abdominal pain: tenderness or continuous pain in physical examination; rash: red skin 
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discoloration that disappears with pressure; itching; nausea; diarrhea: three or more loose 
stools per day; vomiting: three or more episodes per day; hepatomegaly: liver enlargement 
>2cm; jaundice; oligoanuria; cough; dyspnea; tachypnea: respiratory frequency greater than 
20 breaths/minute; hemorrhagic syndrome: including mucosal bleeding, abundant 
menstruation and/or blood in urine. All clinical symptoms were considered absent or present. 
 Laboratory parameters were considered present or absent based of the following 
definitions: leukopenia -leukocyte count lower than 4,000/mm3 and thrombocytopenia-platelet 
count lower than 150,000/ mm3. 
 The pre-existing immunity to DENV was determined by PanBio Dengue IgG Capture 
ELISA (Australia), in order to distinguish between primary and secondary DENV infections. 
 
Statistical Analysis 
Data were analyzed using the chi-square test for categorical variables. Univariate 
logistic regression analyses were performed to investigate the association of relevant 
independent variables with the outcomes (e.g. DWoWS vs. DWWS) and odds ratios were 
calculated where appropriate. Multivariate analyses used a logistic regression model, 
adjusting odds ratios for age, sex and previous exposure to DENV. The Mann-Whitney test 
was used for continuous variables. P-values were calculated during regression analysis 
using a 2-tailed test. A p value <0.05 was considered significant for all the tests performed. 
Statistical analyses were performed using Stata/SE 13.0 for Windows (StataCorp LP, 
College Station, TX, USA). 
 
Ethics Statement 
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 This study was approved by San Vicente de Paul Hospital, Buenos Aires, Argentina, 
and Bioethics Committee of Facultad de Medicina, Universidad Nacional de Tucumán, 
Tucumán, Argentina. 
 
RESULTS 
 
Population Characteristics 
 Among the 301 patients with laboratory-confirmed dengue who received care at San 
Vicente de Paul Hospital between February and June 2014, 37.9% presented DWWS and 
62.1% DWoWS. No SD cases or deaths were reported. Patient ages ranged from 2-86 years 
with a mean (standard deviation) age of 35.5 (16.9) years (Table I). The mean age of DWWS 
patients was 37.3 (17.2), while the mean age of DWoWS patients was 34.4 (16.6).The most 
frequent clinical manifestations were headache (94.7%), myalgia (93.0%), arthralgia (88.0%), 
retro-orbital pain (78.1%) and rash (54.5%). DWWS patients also exhibited significantly 
higher frequencies of conjunctival injection (56.1% vs. 29.4%), diarrhea (32.5% vs. 11.2%), 
cough (15.8% vs. 5.9%) and dyspnea (11.4% vs. 3.2%) compared to DWoWS patients. 
Though these symptoms are not warning signs, multivariate analyses revealed that 
conjunctival injection (OR=3.02; 95% CI=1.67–5.47; p<0.001) and diarrhea (OR=3.10; 95% 
CI=1.48–6.49; p=0.003) are associated with a significantly increased risk of DWWS. Among 
the patients who presented warning signs, 28.9% presented multiple warning signs. The 
most frequent warning signs were abdominal pain (27.9%) and thrombocytopenia (22.0%). 
 When pre-existing immunity to DENV was analyzed in the study population, we found 
that nearly half of patients had secondary dengue infections (47.1%; Table I). In addition, 
secondary infections were not correlated to DWWS (59.3% with DWoWS vs. 40.7% with 
DWWS; Table I).  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
8 
 
 
 Interestingly, 11% of the patients with laboratory-confirmed dengue did not report 
fever. These patients also reported significantly lower frequencies of headache, conjunctival 
injection and myalgia (Figure 2). All other symptoms were reported at frequencies similar to 
those reported by febrile patients (Table SI). 
 
Association of clinical manifestations and age 
 Several reports have described an association of dengue severity with age 6,7. In this 
study, no significant differences were found in the incidence of DWWS between age groups 
(26.5% for <15 years vs. 39.3% for >15 years; Table II), nor was there any significant 
correlation between the incidence of secondary infection and age groups (50.0% for <15 
years vs. 46.8% for >15 years; Table II). Univariate and multivariate analyses revealed that 
patients over 15 years of age had a significantly increased risk of fever, retro-orbital pain, 
arthalgia, diarrhea and thrombocytopenia compared to younger patients. Conversely, 
pediatric patients (2-14) were two times more likely to present rash than older patients (Table 
II). 
 
Clinical manifestations by sex 
 Previous studies have described differences in dengue presentation based on sex 
18,20-22. Nearly 56% of the participants in our study were female and these patients had a 
significantly higher rate of DWWS compared to men (43.1% vs. 31.3%; Table III). Although 
univariate analysis showed that females had an increased risk of developing DWWS, this risk 
was no longer significant when adjusted for age and pre-existing immunity to DENV (Table 
III). When previous exposure to DENV was studied, male and female patients were found to 
have similar rates of secondary infection. However, multivariate logistic regression model 
showed that female patients had a significantly increased risk of rash, nausea, diarrhea, 
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abdominal pain and leukopenia (Table III). All other symptoms were reported at rates similar 
to those reported by men. 
 
DISCUSSION 
 
 This study found variations in disease severity, clinical manifestations and laboratory 
parameters between pediatric and adult patients with laboratory-confirmed DENV infections. 
While there is a body of published work describing a relationship between age and dengue 
severity, the nature of this relationship is unclear and may be complicated by confounding 
factors. A three-year study of hospitalized DENV patients in Nicaragua found that infants and 
children aged 4-6 years were more likely to develop severe disease than adults 6. Similarly, a 
Cuban study reported that secondary DENV infections in children aged 3-15 years were 14.5 
times more likely to be fatal than secondary infections in adults aged 16 to 39 years 23. 
However, prospective school-cohort studies of DENV infections in children have reported 
approximately twice as many inapparent cases as symptomatic cases  24,25, and a recent  
review suggests that the majority of DENV infections are subclinical 19. The current study 
found that children were significantly less likely to present fever, a symptom which is 
frequently considered the minimum symptom in defining symptomatic infections 19 and is 
critical in the WHO diagnostic guidelines 4.  
 The children in this study did not only present milder illness than adults, but they 
presented a distinct profile of clinical manifestations, characterized by significantly reduced 
risk of fever, retro-orbital pain, arthalgia, diarrhea and thrombocytopenia and increased risk 
of developing rash compared to adult patients. The absence of fever in almost 25% of 
children, especially accompanied by the dramatically reduced rates of thrombocytopenia, 
may cause these dengue cases to be overlooked. Mild and inapparent primary DENV 
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infection can prime a population for more severe disease in subsequent heterotypic 
outbreaks. In fact, longer intervals between heterotypic outbreaks have been associated with 
increased mortality 26,27. Furthermore, viremic patients with inapparent illness have been 
shown to effectively transmit DENV to mosquitoes 28. Given this background, asymptomatic, 
mild and non-febrile patients are vital to understanding and controlling DENV transmission 
and epidemic cycles in a public health context and highlight the need to monitor pediatric 
populations during outbreaks.  
 While half of children under 15 years old had secondary dengue infections, incidence 
of secondary infection was lower in younger children; in fact, 80 % of children under 10 years 
old had primary infections. Given that the 1998 outbreak of DENV-2 in Salta represented the 
first dengue cases reported in the country in over 80 years 12, the lack of association 
between incidence of secondary infection and age is unsurprising. Between 1998 and 2014, 
DENV circulated regionally in epidemic cycles, giving older children and adults in Oran a 
similar lifetime risk of exposure to DENV 13,14.  
 Virus serotype has been associated with disease severity and differential 
characteristic clinical manifestations 10,29,30. Consistent with our findings, previous studies 
have described relatively mild disease during DENV-4 outbreaks 10,31-33. A prospective six-
year study of over 2,000 dengue infections found that, unlike serotypes 1-3, over half of 
DENV-4 infections in children were inapparent 27. One 12-year retrospective study in 
Thailand found that DENV-4 was half as likely as DENV-2 or DENV-3 to result in severe 
disease during a secondary infection 9.These findings are consistent with the results of the 
current study, in which none of the patients developed severe disease despite a moderate 
incidence of secondary infections. Interestingly, 63% of the patients reported cutaneous 
symptoms, which is consistent with previous DENV-4 outbreaks, but represents a higher 
incidence than has been reported for other serotypes 10. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
11 
 
 
 This study reports sex-based differences in the manifestations of DENV infection. 
Similar results have been reported in Mexico City 18,in French Caribbean islands 20 and in 
select Chinese localities 21. One study in Korea, a country in which DENV is almost 
exclusively imported by travelers, found significantly higher DENV incidence in men 22. 
Further investigation will be necessary to define whether these differences are due to 
physiological or to regional socio-behavioral factors.  
 In summary, clinical manifestations and laboratory abnormalities between pediatric 
and adult patients infected with DENV-4 exhibited significant differences. Variations were 
also noted in presentations in females compared to males. A better understanding of these 
differences should contribute to better assessment of emerging and re-emerging DENV 
infections in at risk regions.  
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FIGURE LEGENDS 
 
Figure 1. Geographical location of the study. The city San Ramon de la Nueva Orán 
(Orán) is located in the province of Salta on the Northwestern border of Argentina, 270 km 
Northeast of the province capital Salta and 30 km South of Bolivia. 
 
Figure 2. Differences in clinical manifestations between febrile and non-febrile 
patients. Patients with laboratory confirmed dengue who presented without fever also 
exhibited significantly lower frequencies of headache, myalgia and conjunctival injection 
(abbreviated as Conjun. Inj.). Data were analyzed using the chi-square test for categorical 
variables. A p value <0.05 was considered significant. 
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Table I. Demographics, constitutional, musculoskeletal, cutaneous, gastrointestinal, respiratory and 
hemorrhagic manifestations and laboratory parameters of patients, categorized by the WHO 
diagnostic guidelines. 
Characteristics Total DWoWS DWWS p (Chi2) 
 
n (%) n (%) n (%) 
 
Demographic 
    
Number of patients 301 187 (62.1) 114 (37.9) ---- 
Mean age in years (StD) 35.5 (16.9) 34.4 (16.6) 37.3 (17.2) 0.133a 
Age range in years 2-86 2-78 6-86 ---- 
Female (%) 167 (55.5) 95 (50.8) 72 (63.2) 0.036 
Constitutional 296 (98.3) 182 (97.3) 114 (100) 0.078 
Fever 268 (89.0) 154 (82.4) 114 (100) <0.001 
Headache 285 (94.7) 177 (94.7) 108 (94.7) 0.975 
Retro-orbital pain 235 (78.1) 140 (74.9) 95 (83.3) 0.085 
Bipalpebral edema  6 (2.0) 3 (1.6) 3 (2.6) 0.536 
Conjunctival injection 119 (39.5) 55 (29.4) 64 (56.1) <0.001 
Musculoskeletal 283 (94.0) 171 (91.4) 112 (98.3) 0.016 
Myalgia 280 (93.0) 169 (90.4) 111 (97.4) 0.021 
Arthralgia 265 (88.0) 162 (86.6) 103 (90.4) 0.335 
Cutaneous 190 (63.1) 114 (61.0) 76 (66.7) 0.320 
Rash 164 (54.5) 99 (52.9) 65 (57.0) 0.491 
Itching 128 (42.5) 73 (39.0) 55 (48.3) 0.117 
Gastrointestinal  157 (52.2) 65 (34.8) 92 (80.7) <0.001 
Nausea 113 (37.5) 43 (23.0) 70 (61.4) <0.001 
Diarrhea 58 (19.3) 21 (11.2) 37 (32.5) <0.001 
Vomiting 43 (14.3) 4 (2.1) 39 (34.2) <0.001 
Abdominal pain 84 (27.9) 18 (9.6) 66 (57.9) <0.001 
Hepatomegaly 4 (1.3) 1 (0.5) 3 (2.6) 0.123 
Jaundice 3 (1.0) 1 (0.5) 2 (1.8) 0.301 
Oligoanuria 2 (0.7) 0 (0) 2 (1.8) 0.069 
Respiratory 37 (12.3) 15 (8.0) 22 (19.3) 0.004 
Cough 29 (9.6) 11 (5.9) 18 (15.8) 0.005 
Dyspnea 19 (6.3) 6 (3.2) 13 (11.4) 0.005 
Tachypnea 7 (2.3) 4 (2.1) 3 (2.6) 0.783 
Hemorrhagic syndrome 5 (1.7) 0 (0) 5 (4.4) 0.004 
  
    
Laboratory abnormalities 
   
Leukopenia 111 (44.0) 54 (35.5) 57 (59.4) <0.001 
Thrombocytopenia 54 (22.0) 12 (8.0) 42 (44.2) <0.001 
Incidence of SI 140 (47.1) 83 (59.3) 57 (40.7) 0.435 
 
Definition of abbreviations: DWWS= dengue with warning signs; DWoWS= dengue without warning 
signs; SI= secondary infection; StD= standard deviation. 
a p-value was calculated using the Mann-Whitney Rank Sum test for non-categorical variables. 
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Table II. Characteristics of pediatric and adult patients and odds ratios for age-associated symptoms. 
Characteristics <15 years ≥15 years p (Chi2) Crude OR  Adjusted ORa  
 n (%) n (%)  OR 95% CI pb OR 95% CI pb 
Number of patients 34 (11.3) 267 (88.7) --- --- --- --- --- --- --- 
Mean age in years 
(StD) 
10.4 (3.3) 38.7 (15.1) --- --- --- --- --- --- --- 
Age range in years 2-14 15-86 --- --- --- --- --- --- --- 
Female (%) 17 (50.0) 150 (56.2) 0.495 --- --- --- --- --- --- 
Incidence of DWWS 9 (26.5) 105 (39.3) 0.146 --- --- --- --- --- --- 
Incidence of SI 17 (50.0) 123 (46.8) 0.722 --- --- --- --- --- --- 
Symptoms          
Fever 26 (76.5) 242 (90.6) 0.013 3.0 1.22-7.27 0.017 3.0 1.21-7.26 0.017 
Retro-orbital pain 20 (58.8) 215 (80.5) 0.004 2.9 1.37-6.11 0.005 2.9 1.35-6.05 0.006 
Arthralgia 26 (76.5) 239 (89.5)  0.027 2.6 1.02-6.36 0.032 2.6 1.06-6.28 0.037 
Rash 24 (70.6) 140 (52.4) 0.045 0.5 0.211-0.99 0.049 0.4 0.20-0.98 0.045 
Diarrhea 1 (2.9) 57 (21.4) 0.010 9.0 1.15-65.34 0.036 8.9 1.19-67.98 0.034 
Thrombocytopenia 1 (3.6) 53 (24.3) 0.013 8.7 1.15-65.36 0.036 8.9 1.17-67.06 0.034 
Definition of abbreviations: StD= standard deviation; DWWS= dengue with warning signs; SI= 
secondary infection; OR= Odds ratio; CI= confidence interval. 
a Logistic regression model, adjusted for sex and previous exposure to DENV. 
b p-values were calculated during univariate or multivariate analyses using a 2-tailed test. 
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Table III. Characteristics of male and female patients and odds ratios for sex-associated symptoms. 
Characteristics Male Female p (Chi2) Crude OR  Adjusted ORb  
 n (%) n (%)  OR 95% CI pc OR   95% CI pc 
Number of patients 134 (44.5) 167 (55.5) ---- --- --- --- --- --- --- 
Mean age in years 
(StD) 
33.7 (16.9) 36.9 (16.7) 0.059a --- --- --- --- --- --- 
Age range in years 2-78 4-86 ---- --- --- --- --- --- --- 
Incidence of DWWS 42 (31.3) 72 (43.1) 0.036 1.7 1.03-2.67 0.037 1.8 0.81-4.07 0.147 
Incidence of SI 59 (45.0) 81 (48.8) 0.520 --- --- --- --- --- --- 
Symptoms          
Rash 63 (47.0) 101 (60.5) 0.020 1.7 1.08-2.73 0.020 1.8 1.10-2.82 0.018 
Nausea 38 (28.4) 75 (44.9) 0.003 2.1 1.27-3.34 0.003 2.1 1.26-3.37 0.004 
Diarrhea 18 (13.4) 40 (24.0) 0.021 2.0 1.10-3.74 0.023 2.0 1.05-3.63 0.034 
Abdominal pain 28 (20.9) 56 (33.5) 0.015 2.2 1.13-3.23 0.016 1.9 1.11-3.19 0.019 
Leukopenia 40 (34.8) 71 (53.4) 0.003 2.2 1.28-3.59 0.004 2.2 1.29-3.65 0.004 
Definition of abbreviations: StD= standard deviation; DWWS= dengue with warning signs; SI= 
secondary infection; OR= Odds ratio; CI= confidence interval. 
a p-value was calculated using the Mann-Whitney Rank Sum test for non-categorical variables. 
b Logistic regression model, adjusted for age and previous exposure to DENV. 
c p-values were calculated during univariate or multivariate analysis using a 2-tailed test. 
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Figure 1 
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Figure 2 
